888072-88-6

Basic information

• Product Name: N-[4-cyano-2-iodo-5-(trifluoromethyl)phenyl]-2-methyl-prop-2-enamide
• CAS NO: 888072-88-6
• Molecular Formula: C₁₂H₈F₃IN₂O
• Molecular Weight: 380.1043996
• Mol File: 888072-88-6.mol

Chemical Properties

• CAS DataBase Reference: N-[4-cyano-2-iodo-5-(trifluoromethyl)phenyl]-2-methyl-prop-2-enamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-cyano-2-iodo-5-(trifluoromethyl)phenyl]-2-methyl-prop-2-enamide(888072-88-6)
• EPA Substance Registry System: N-[4-cyano-2-iodo-5-(trifluoromethyl)phenyl]-2-methyl-prop-2-enamide(888072-88-6)

Safety Data

• Hazardous Substances Data: 888072-88-6(Hazardous Substances Data)

Upstream product

• 852569-35-8 4-amino-5-iodo-2-(trifluoromethyl)benzonitrile 
• 920-46-7 Methacryloyl chloride 

Relevant articles and documents

Design, synthesis, and in vivo SAR of a novel series of pyrazolines as potent selective androgen receptor modulators

A novel series of pyrazolines 2 have been designed, synthesized, and evaluated by in vivo screening as tissue-selective androgen receptor modulators (SARMs). Structure-activity relationships (SAR) were investigated at the R 1 to R6 positions as well as the core pyrazoline ring and the anilide linker. Overall, strong electron-withdrawing groups at the R 1 and R2 positions and a small group at the R5 and R6 position are optimal for AR agonist activity. The (S)-isomer of 7c exhibits more potent AR agonist activity than the corresponding (R)-isomer. (S)-7c exhibited an overall partial androgenic effect but full anabolic effect via oral administration in castrated rats. It demonstrated a noticeable antiandrogenic effect on prostate in intact rats with endogenous testosterone. Thus, (S)-7c is a tissue-selective nonsteroidal androgen receptor modulator with agonist activity on muscle and mixed agonist and antagonist activity on prostate.

NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS)

The present invention is directed to novel heterocycle derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.